在动脉样硬化中CLEC5A和ISG20的因果推断:整合孟德尔随机化和eQTL证据
Ya Zhang1, Qian Tian2, Yuan Zhu1
1Comprehensive Ward, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Frontiers in immunology
|December 19, 2025
概括
干扰素刺激基因20 (ISG20) 通过增加巨细胞脂质积累和炎症来促进动脉样硬化. 这一发现将ISG20确定为治疗动脉样硬化的潜在治疗标.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 动脉样硬化 (AS) 是一种由脂质积累和炎症驱动的血管疾病.
- 遗传和免疫因素显著影响AS的发病.
研究的目的:
- 为了识别与动脉样硬化相关的基因.
- 调查已识别的基因在AS发展中的功能作用.
主要方法:
- 综合基因表达综合 (GEO) 数据与表达定量特征位置 (eQTL) 和门德尔随机化 (MR) 分析.
- 在巨细胞和小鼠模型中进行功能丰富分析和实验验证.
主要成果:
- 在AS患者中,CLEC5A和ISG20上调,MR分析显示与AS风险的因果关系.
- 功能分析将CLEC5A和ISG20与免疫反应,炎症和脂质代谢联系起来.
- 实验模型证实了AS斑块中的ISG20上调,并证明了它在巨细胞脂质积累中的作用.
结论:
- ISG20通过巨细胞脂质积累和炎症促进AS的进展.
- ISG20代表了动脉样硬化的潜在新型治疗标.
相关概念视频
Atherosclerosis I: Introduction
795
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
795
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
434
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
434
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Pleiotropy
43.1K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
43.1K
Coronary Artery Disease I: Introduction
847
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
847
Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K

